JPRN-UMIN000014855已完成2 期
A phase II trial of personalized peptide vaccination for rare cancer or primary unknown cancer patients - A phase II trial of personalized peptide vaccination for rare cancer or primary unknown cancer patients
Kurume University Cancer Vaccine Center0 个研究点目标入组 200 人开始时间: 2014年8月14日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency and disturbance of coagulation). 2)Patients with the past history of severe allergic reactions. 3)(Female) Patients who are pregnancy,lactation and hope the graviditas. (male) Patient who do not agree prevebt pregnancy. 4)Patients who are judged inappropriate for entry to this clinical trial by doctor in charge.
研究者
相似试验
已完成
2 期
A phase II trial of personalized peptide vaccination for nine kinds of cancersProstate cancer, Urothelial cancer, Breast cancer, Lung cancer, Ovarian cancer, Gastric cancer, Colon cancer, Liver cancer, Pancreatic cancerJPRN-UMIN000029789Kurume University900
已完成
2 期
A phase II trial of personalized peptide vaccination for several cancer patients with slight bone marrow suppressioCancer patients who are under standard treatments or resistant to standard treatments with slight bone marrow suppressionJPRN-UMIN000019390Kurume University Cancer Vaccine Center1,000
已完成
2 期
Phase II study of personalized peptide vaccination in bladder cancer patients progressing after first-line platinum-containing regimeBladder cancerJPRN-UMIN000003157Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division80
已完成
1 期
A phase I trial of personalized peptide vaccination using long and short peptides in patients with metastatic cancer resistant to standard treatmentsMetastatic cancer resistant to standard treatmentsJPRN-UMIN000013029Kurume University Cancer Vaccine Center10
已完成
不适用
Phase I study of personalized peptide vaccination with transdermal adjuvant for cancer patientsmalignant tumorJPRN-UMIN000030854Kurume University10